Final report of the phase I trial of continuous infusion etanidazole (SR 2508): A radiation therapy oncology group study
- 31 December 1992
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 22 (3), 577-580
- https://doi.org/10.1016/0360-3016(92)90880-q
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Final report of the phase i trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) radiation therapy oncology group 83-03International Journal of Radiation Oncology*Biology*Physics, 1990
- Glutathione depletion and cytotoxicity of buthionine sulphoximine and SR2508 in rodent and human cellsInternational Journal of Radiation Oncology*Biology*Physics, 1990
- Initial results of a phase i trial of continuous infusion SR 2508 (etanidazole): A radiation therapy oncology group studyInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Chemical modifiers of cancer treatment.Journal of Clinical Oncology, 1988
- Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508International Journal of Radiation Oncology*Biology*Physics, 1984
- Clinical trials of radiosensitizers: What should we expect?International Journal of Radiation Oncology*Biology*Physics, 1984
- The enhanced sensitivity of mammalian cells to killing by X rays after prolonged exposure to several nitroimidazolesInternational Journal of Radiation Oncology*Biology*Physics, 1982
- SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical useInternational Journal of Radiation Oncology*Biology*Physics, 1981